03.12.2020
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
Press releases
19.11.2020
DEINOVE signs an Evaluation and Technology Development License with DSM
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment...
12.11.2020
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the protocol of the ongoing Phase...
01.10.2020
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
15.07.2020
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...
17.06.2020
Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020
Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships
• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
29.04.2020
2019 Annual results: A year of important milestones in both Antibiotics and Cosmetics activities
Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...
23.04.2020
Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion
Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion...
03.04.2020
Issuance of a 2nd tranch of €1 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position by €1 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses...